{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:07:44Z","timestamp":1790770064142,"version":"4.1.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Our group has recently demonstrated that chimeric antigen receptor T-cell therapy targeting the CD30 antigen (CD30.CAR-T) is highly effective in patients with relapsed and refractory (r\/r) classical Hodgkin lymphoma (cHL). Despite high rates of clinical response, relapses and progression were observed in a subset of patients. The objective of this study was to characterize clinical and correlative factors associated with progression-free survival (PFS) after CD30.CAR-T cell therapy. We evaluated correlatives in 27 patients with r\/r cHL treated with lymphodepletion and CD30.CAR-T cells. With a median follow-up of 9.5 months, 17 patients (63%) progressed, with a median PFS of 352 days (95% confidence interval: 116-not reached), and 2 patients died (7%) with a median overall survival of not reached. High metabolic tumor volume (MTV, &amp;gt;60 mL) immediately before lymphodepletion and CD30.CAR-T cell infusion was associated with inferior PFS (log rank, P = .02), which persisted after adjusting for lymphodepletion and CAR-T dose (log rank, P = .01 and P = .006, respectively). In contrast, receiving bridging therapy, response to bridging therapy, CD30.CAR-T expansion\/persistence, and percentage of CD3+PD-1+ lymphocytes over the first 6 weeks of therapy were not associated with differences in PFS. In summary, this study reports an association between high baseline MTV immediately before lymphodepletion and CD30.CAR-T cell infusion and worse PFS in patients with r\/r cHL. This trial was registered at www.clinicaltrials.gov as #NCT02690545.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005385","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T22:39:04Z","timestamp":1634769544000},"page":"1255-1263","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":49,"title":["Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-6454","authenticated-orcid":false,"given":"Timothy J.","family":"Voorhees","sequence":"first","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"},{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Gillings School of Public Health,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Oldan","sequence":"additional","affiliation":[{"name":"Department of Radiology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hucks","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"},{"name":"Department of Pediatrics, University of North Carolina, Chapel Hill, NC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3629-5472","authenticated-orcid":false,"given":"Amir","family":"Khandani","sequence":"additional","affiliation":[{"name":"Department of Radiology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dittus","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"},{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Smith","sequence":"additional","affiliation":[{"name":"Gillings School of Public Health,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Kaitlin","family":"Morrison","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5674-6408","authenticated-orcid":false,"given":"Steven","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Shea","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"},{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne W.","family":"Beaven","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"},{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpietro","family":"Dotti","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4568-1092","authenticated-orcid":false,"given":"Jonathan","family":"Serody","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"},{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Savoldo","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"},{"name":"Department of Pediatrics, University of North Carolina, Chapel Hill, NC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie","family":"Grover","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"},{"name":"Division of Hematology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"issue":"26","key":"2022021616292799400_B1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"2022021616292799400_B2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med."},{"issue":"14","key":"2022021616292799400_B3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med."},{"issue":"8","key":"2022021616292799400_B4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med."},{"issue":"32","key":"2022021616292799400_B5","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol."},{"issue":"27","key":"2022021616292799400_B6","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol."},{"key":"2022021616292799400_B7","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1182\/blood-2019-129107","article-title":"Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma patients in the Juliet Trial","volume":"134","author":"Westin","year":"2019","journal-title":"Blood."},{"key":"2022021616292799400_B8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-137045","article-title":"Myc expression and tumor-infiltrating T cells are associated with response in patients (pts) with relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL) treated with tisagenlecleucel in the Juliet trial","volume":"136","author":"Jaeger","year":"2020","journal-title":"Blood."},{"issue":"17","key":"2022021616292799400_B9","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood."},{"issue":"14","key":"2022021616292799400_B10","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv."},{"issue":"22","key":"2022021616292799400_B11","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv."},{"issue":"15","key":"2022021616292799400_B12","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"30","key":"2022021616292799400_B13","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J Clin Oncol."},{"issue":"11","key":"2022021616292799400_B14","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","author":"Sasanelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"13","key":"2022021616292799400_B15","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood."},{"issue":"1","key":"2022021616292799400_B16","doi-asserted-by":"crossref","first-page":"e0210224","DOI":"10.1371\/journal.pone.0210224","article-title":"Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis","volume":"14","author":"Guo","year":"2019","journal-title":"PLoS One."},{"issue":"9","key":"2022021616292799400_B17","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","article-title":"Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma","volume":"41","author":"Kanoun","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"20","key":"2022021616292799400_B18","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","article-title":"Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood."},{"issue":"1","key":"2022021616292799400_B19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbmt.2017.09.006","article-title":"positron emission tomography-based assessment of metabolic tumor volume predicts survival after autologous hematopoietic cell transplantation for Hodgkin lymphoma","volume":"24","author":"Proch\u00e1zka","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2022021616292799400_B20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/s12885-018-4432-4","article-title":"Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin\u2019s lymphoma","volume":"18","author":"Rogasch","year":"2018","journal-title":"BMC Cancer."},{"issue":"27","key":"2022021616292799400_B21","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022021616292799400_B22","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest."},{"issue":"7858","key":"2022021616292799400_B23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-021-03442-1","article-title":"Cell-programmed nutrient partitioning in the tumour microenvironment","volume":"593","author":"Reinfeld","year":"2021","journal-title":"Nature."},{"issue":"19","key":"2022021616292799400_B24","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"issue":"1","key":"2022021616292799400_B25","doi-asserted-by":"crossref","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","article-title":"PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy?","volume":"7","author":"Simon","year":"2017","journal-title":"OncoImmunology."},{"issue":"1","key":"2022021616292799400_B26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13045-021-01120-3","article-title":"Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed\/relapsed after CART19\/20 therapy [correction published in J Hematol Oncol. 2021;14:150]","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol Oncol."},{"issue":"8","key":"2022021616292799400_B27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood."},{"key":"2022021616292799400_B28","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","article-title":"Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas","volume":"132","author":"Chong","year":"2018","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/4\/1255\/1871788\/advancesadv2021005385.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/4\/1255\/1871788\/advancesadv2021005385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T16:30:22Z","timestamp":1645029022000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/4\/1255\/477391\/Pretherapy-metabolic-tumor-volume-is-associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,2,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005385","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]}}}